Postmarketing studies: can they provide a safety net for COVID-19 vaccines in the UK? | BMJ Evidence-Based Medicine

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

EBM analysis

Postmarketing studies: can they provide a safety net for COVID-19 vaccines in the UK?

Online download statistics by month:

Online download statistics by month: October 2020 to March 2024

	Abstract	Full	Pdf
Oct 2020	449	439	173
Nov 2020	906	886	172
Dec 2020	588	583	133
Jan 2021	542	533	138
Feb 2021	462	452	112
Mar 2021	302	294	95
Apr 2021	232	221	83
May 2021	315	306	73
Jun 2021	219	213	58
Jul 2021	174	164	47
Aug 2021	205	195	59
Sep 2021	178	165	39
Oct 2021	253	244	61
Nov 2021	127	116	47
Dec 2021	107	98	21
Jan 2022	346	344	85
Feb 2022	282	259	72
Mar 2022	224	207	71
Apr 2022	146	122	53
May 2022	95	74	35
Jun 2022	96	78	34
Jul 2022	73	59	24
Aug 2022	88	71	25
Sep 2022	78	70	29
Oct 2022	87	75	25
Nov 2022	60	45	15
Dec 2022	57	47	14
Jan 2023	69	68	25
Feb 2023	59	56	6
Mar 2023	71	61	19
Apr 2023	58	55	17
May 2023	54	43	26
Jun 2023	37	34	14
Jul 2023	48	43	18
Aug 2023	24	22	13
Sep 2023	39	39	5
Oct 2023	72	65	13
Nov 2023	67	57	18
Dec 2023	51	36	9
Jan 2024	88	87	13
Feb 2024	52	52	4
Mar 2024	77	70	10
Total	7557	7148	2003